Condition: Nausea and Vomiting · Obesity · Sponsor: Vanda Pharmaceuticals
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
This description comes directly from the study's public registry record.
Vanda Pharmaceuticals · (202) 734-3400 · clinicaltrials@vandapharma.com
Always discuss trial participation with your own doctor first.
| Vanda Investigational Site | Los Angeles, California, United States | Recruiting |
| Vanda Investigational Site | San Diego, California, United States | Recruiting |
| Vanda Investigational Site | San Jose, California, United States | Not Yet Recruiting |
| Vanda Investigational Site | Tampa, Florida, United States | Recruiting |
| Vanda Investigational Site | Hamilton, New Jersey, United States | Not Yet Recruiting |
| Vanda Investigational Site | New York, New York, United States | Not Yet Recruiting |
| Vanda Investigational Site | Syosset, New York, United States | Not Yet Recruiting |
| Vanda Investigational Site | Plano, Texas, United States | Not Yet Recruiting |
| Vanda Investigational Site | San Antonio, Texas, United States | Not Yet Recruiting |
| Vanda Investigational Site | Burke, Virginia, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07446439